Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Aug 29;5(9):763-766.
doi: 10.1016/j.jdcr.2019.06.026. eCollection 2019 Sep.

Concurrent radiation therapy with programmed cell death protein 1 inhibition leads to a complete response in advanced cutaneous squamous cell carcinoma

Poorva Vaidya  1 , Arjun Mehta  2 , Omar Ragab  3 , Sonia Lin  1 , Gino K In  4
Affiliations
Case Reports

Concurrent radiation therapy with programmed cell death protein 1 inhibition leads to a complete response in advanced cutaneous squamous cell carcinoma

Poorva Vaidya et al. JAAD Case Rep. .
No abstract available

Keywords: CSCC, cutaneous squamous cell carcinoma; PD-1 inhibition; PD-1, programmed cell death protein 1; PD-L1, programmed death ligand 1; PD-L2, programmed death ligand 2; cemiplimab; cutaneous squamous cell carcinoma; immunotherapy; pembrolizumab; radiation.

PubMed Disclaimer

Figures

Fig 1
Fig 1
A and B, Hematoxylin-eosin–stained sections show poorly differentiated carcinoma arranged in sheets and associated with scarring. The poorly differentiated areas stain with cytokeratin 5/6 and p40 immunohistochemical stains, which confirm a squamous origin.
Fig 2
Fig 2
The patient's lesion in June 2017, 3 weeks after completing radiation therapy 66 Gy in 33 fractions and receiving 2 cycles of pembrolizumab.
Fig 3
Fig 3
Radiation plan. The red line shows the 66-Gy isodose line. The red colorwash shows the clinical tumor volume (gross disease +2-cm lateral margin). The blue colorwash shows the planning tumor volume, expanded 5 mm from the clinical tumor volume.
Fig 4
Fig 4
Complete regression of the patient's lesion in May 2018, after radiation and 16 cycles of pembrolizumab.
See this image and copyright information in PMC

References

    1. Rogers H.W., Weinstock M.A., Feldman S.R., Coldiron B.M. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol. 2015;151(10):1081–1086. - PubMed
    1. Que S.K.T., Zwald F.O., Schmults C.D. Cutaneous squamous cell carcinoma: incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol. 2018;78(2):237–247. - PubMed
    1. Malm I.-J., Bruno T.C., Fu J. Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma. Head Neck. 2015;37(8):1088–1095. - PMC - PubMed
    1. Stevenson M.L., Wang C.Q.F., Abikhair M. Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab. JAMA Dermatol. 2017;153(4):299–303. - PubMed
    1. Migden M.R., Rischin D., Schmults C.D. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341–351. - PubMed

Publication types